secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2024-07-22T23:59:59+00:00
Accession:  0000950170-24-085347
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma halts voruciclib, cuts workforce, CEO/CMO depart, evaluates wind-down
--------------------------------------------------------------------------------

- Board unanimously begins evaluation of strategic alternatives including transactions or orderly wind-down.
- Reduction-in-force commencing; clinical development of voruciclib discontinued.
- CEO David Urso and CMO Richard Ghalie step down Aug 1, 2024; CFO Justin File appointed Acting CEO.
- Expected restructuring charges of ~$5.8 million in Q1 fiscal 2025 for one-time employee termination costs.
- Charles Baltic steps down as Chairperson; Frederick Driscoll appointed as Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024085347/0000950170-24-085347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024085347/meip-20240722.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-085347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer